Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GIAPREZA vs EPANED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
A synthetic form of human angiotensin II, a vasoconstrictor that increases blood pressure by binding to angiotensin II type 1 receptors (AT1) on vascular smooth muscle, causing vasoconstriction.
Epaned contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II formation, decreasing vasoconstriction, aldosterone secretion, and sodium reabsorption.
Increase blood pressure in adults with septic or other distributive shock
Treatment of hypertension,Heart failure (adjunctive therapy with diuretics and digitalis),Asymptomatic left ventricular dysfunction (to reduce the risk of developing overt heart failure)
1 mg/kg/min IV continuous infusion, titrated to achieve target mean arterial pressure; maximum dose 10 mg/kg/min.
0.2 mg/kg intravenously over 5 minutes every 2 hours; typical adult dose 10-20 mg IV.
Terminal elimination half-life is approximately 1 hour (range 0.5–2 hours); clinical context: requires continuous intravenous infusion for sustained vasopressor effect.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and 15-20 hours in severe impairment (Cr Cl <30 m L/min).
Metabolized by aminopeptidase A and angiotensin-converting enzyme (ACE) to smaller fragments, including angiotensin (1-8).
Enalapril is extensively metabolized in the liver by ester hydrolysis to its active form, enalaprilat. No significant CYP450 metabolism.
Primarily via proteolysis; renal excretion of unchanged drug is negligible (<1%). Fecal excretion is minimal.
Renal excretion of unchanged drug accounts for approximately 30-40% of elimination; biliary/fecal excretion accounts for 50-60% as metabolites and unchanged drug.
~70% bound to plasma proteins, primarily to albumin.
Approximately 85-90% bound to serum albumin.
Approximately 0.5 L/kg; indicates distribution primarily within extracellular fluid and plasma volume.
0.5-0.7 L/kg, indicating distribution primarily into extracellular fluid.
Intravenous: 100% (only route of administration; oral bioavailability is negligible due to peptide degradation).
Oral: 70-80% due to first-pass metabolism; Intravenous: 100%.
No dose adjustment required for renal impairment.
No adjustment required for renal impairment; drug is hepatically cleared.
No dose adjustment required for hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider dose reduction by 75%.
Safety and efficacy not established; no FDA-approved pediatric dosing.
0.2 mg/kg intravenously over 5 minutes every 2 hours; maximum single dose 20 mg.
No specific adjustment recommended; use with caution due to potential cardiovascular comorbidities.
Start at lower end of dosing range (0.1 mg/kg) due to potential for decreased hepatic function and increased sensitivity; monitor for QT prolongation.
No FDA black box warning.
FDA Warning: When pregnancy is detected, discontinue Epaned as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Thromboembolic events (venous and arterial) have been reported; monitor for signs of thrombosis.,Risk of adverse reactions from coadministration with ACE inhibitors (increased response) or angiotensin receptor blockers (increased response).,Concomitant use with vasopressors may require dose adjustment.,Not recommended for patients with high output states (e.g., cardiogenic shock) unless as a rescue therapy.
Angioedema (including laryngeal edema) risk; discontinue immediately and treat appropriately.,Hypotension in volume-depleted patients (e.g., those on diuretics or with heart failure).,Monitor renal function; risk of acute renal failure, especially in bilateral renal artery stenosis.,Hyperkalemia risk, especially in renal impairment, diabetes, or concomitant K+-sparing diuretics/supplements.,Cough (nonproductive, persistent) may occur.,Hepatic failure; rare but reported. Discontinue if jaundice or significant liver enzyme elevation occurs.
No absolute contraindications identified.,Relative contraindications: patients with known hypersensitivity to any component; patients with a history of severe hypertension; patients with a known high risk of arterial or venous thrombosis.
Hypersensitivity to enalapril or any ACE inhibitor,History of angioedema related to previous ACE inhibitor therapy,Hereditary or idiopathic angioedema,Pregnancy (especially second and third trimesters),Concomitant use with aliskiren in patients with diabetes
No known food interactions. GIAPREZA is administered intravenously and does not interact with food.
No specific food interactions. Grapefruit juice does not affect palonosetron metabolism. Avoid alcohol consumption on chemotherapy days as it may worsen nausea or sedation.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental outcomes were observed at doses up to 2.1 times the maximum recommended human dose based on AUC. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: limited data; second and third trimesters: theoretical risk of fetal hypotension and hypoperfusion due to maternal hypotension.
Pregnancy category C. No adequate studies in pregnant women. In animal studies, no evidence of teratogenicity at clinically relevant doses. Risk of fetal harm cannot be ruled out. Use only if potential benefit justifies risk.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Consider developmental and health benefits of breastfeeding along with mother's clinical need for angiotensin II and any potential adverse effects on breastfed infant from drug or underlying maternal condition. M/P ratio not available.
Not known if excreted in human milk. Caution advised. M/P ratio unknown.
No specific dose adjustments recommended for pregnancy. Dose titration based on blood pressure response as in non-pregnant adults. Limited data on pharmacokinetic changes in pregnancy; consider potential increased volume of distribution and altered clearance, but no established dose modification.
No established dose adjustments for pregnancy. Pharmacokinetic changes in pregnancy are not well characterized; use lowest effective dose.
GIAPREZA (angiotensin II) is indicated for the treatment of refractory hypotension in adults with distributive shock who have failed adequate volume resuscitation and other vasopressors. Do not administer with angiotensin-converting enzyme (ACE) inhibitors due to risk of excessive hypotension. Monitor blood pressure continuously during administration. Prepare using strict aseptic technique; discard unused portion. Dosage is based on the patient's baseline mean arterial pressure (MAP) and response. Use with caution in patients with severe hypertension or conditions that may be exacerbated by vasoconstriction.
EPANED (palonosetron) is a 5-HT3 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting (CINV). It has a longer half-life (~40 hours) than other agents in its class, allowing for single-dose protection. It is not effective for breakthrough nausea. Use caution in patients with electrolyte abnormalities or those taking other QT-prolonging drugs, as palonosetron does not significantly prolong QT interval at standard doses. Administer 30 minutes before chemotherapy. For dexamethasone-sparing regimens, consider single-dose palonosetron with dexamethasone.
This medication is used to increase your blood pressure if it is dangerously low and not responding to other treatments.,Your blood pressure will be monitored continuously during the infusion.,Inform your healthcare provider if you have a history of high blood pressure, heart disease, or any allergies.,Do not stop or change the dose without consulting your doctor.,Report any symptoms such as chest pain, shortness of breath, or headache immediately.
Take this medication exactly 30 minutes before your chemotherapy session.,This drug prevents nausea and vomiting; it will not help if you already feel sick.,Common side effects include headache, constipation, or diarrhea; report persistent or severe symptoms.,Avoid driving or operating heavy machinery if you feel drowsy or dizzy after taking this medication.,Do not take any other anti-nausea medications without your doctor's approval.,Keep a diary of any vomiting episodes to share with your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GIAPREZA vs EPANED, answered by our medical review team.
GIAPREZA is a Vasopressor that works by A synthetic form of human angiotensin II, a vasoconstrictor that increases blood pressure by binding to angiotensin II type 1 receptors (AT1) on vascular smooth muscle, causing vasoconstriction.. EPANED is a Vasopressor that works by Epaned contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II formation, decreasing vasoconstriction, aldosterone secretion, and sodium reabsorption.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GIAPREZA and EPANED depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GIAPREZA is: 1 mg/kg/min IV continuous infusion, titrated to achieve target mean arterial pressure; maximum dose 10 mg/kg/min.. The standard adult dose of EPANED is: 0.2 mg/kg intravenously over 5 minutes every 2 hours; typical adult dose 10-20 mg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GIAPREZA and EPANED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GIAPREZA is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental outcomes were observed at doses up to 2.1 times the maximum reco. EPANED is classified as Category C. Pregnancy category C. No adequate studies in pregnant women. In animal studies, no evidence of teratogenicity at clinically relevant doses. Risk of fetal harm cannot be ruled out. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.